Results 181 to 190 of about 2,154,224 (303)

Pain-Related Outcome Domains and Measures in Randomized Controlled Trials of Treatment for Acute Abdominal Pain: A Systematic Review. [PDF]

open access: yesEur J Pain
Kuhlmann L   +7 more
europepmc   +1 more source

Patient‐reported outcomes and medication errors during oral antitumour therapy in paediatrics: Results from the youngAMBORA care programme

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Increasing use of oral antitumour therapeutics (OAT) in paediatrics is associated with numerous advantages, but also with error‐prone aspects. Based on the randomized AMBORA trial including adults treated with various OAT, we developed a tailored pharmacological/pharmaceutical care programme for children and their caregivers during OAT treatment ...
Phyllis Lensker   +4 more
wiley   +1 more source

Giant Ascending Aortic Aneurysm With Atypical Presentation as Abdominal Pain. [PDF]

open access: yesJACC Case Rep
Moreno Dirzo JP   +6 more
europepmc   +1 more source

Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions ...
Jianfeng Xu   +13 more
wiley   +1 more source

A rare case of abdominal pain caused by Enterobius vermicularis. [PDF]

open access: yesBMC Gastroenterol
Shen LF   +5 more
europepmc   +1 more source

Unsupervised machine learning for multi‐system adverse event pattern detection in pharmacovigilance: A proof‐of‐concept analysis of fluoroquinolone reports in FAERS

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
. Aims Traditional pharmacovigilance detects single drug–event associations but cannot readily characterize multi‐system adverse‐event patterns such as fluoroquinolone‐associated disability. We evaluated unsupervised machine learning for this purpose, using fluoroquinolones as an exemplar.
Niaz Chalabianloo   +3 more
wiley   +1 more source

Abdominal Pain and Hyperlactatemia in Thiamine Deficiency: A Case Report. [PDF]

open access: yesCase Rep Pediatr
Campos LM   +4 more
europepmc   +1 more source

Systematic review of clinical trials and cohort studies evaluating HIV post‐exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background We conducted a systematic review of clinical trials and cohort studies on HIV post‐exposure prophylaxis (PEP) regimens to inform updated 2025 Canadian guidelines. Methods We searched Medline and Embase (July 2017–June 2024) for studies reporting on: HIV acquisition, PEP completion, adverse events (AEs) leading to discontinuation and/
Stanley O. Onyegbule   +12 more
wiley   +1 more source

Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin.
Kyungrin Chang   +5 more
wiley   +1 more source

Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged <12 years with atopic dermatitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim For children with atopic dermatitis (AD), dupilumab is available as a prefilled syringe (PFS) from the age of 6 months and as a prefilled pen (PFP) for patients aged ≥2 years, in 200‐ and 300‐mg devices. This substudy of an ongoing open‐label extension study evaluated the pharmacokinetics, efficacy and safety of switching from a dupilumab PFS ...
Amy S. Paller   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy